New possibilities for dyslipidemia correction in patients with diffuse liver changes and gallbladder cholesterosis

Abstract

Background. According to existing data, the decisive role in the development of gallbladder cholesterosis is played by the lipid metabolism violation of the body. In this regard, the most important stage in the complex treatment of this disease is correction of the detected lipid disorders in the patient, which contributes to regression and stopping the pathological process progression in the gallbladder wall. Materials and methods. In this work the safety and efficacy of using the drug Vazosponin (Vifitech, Russia) in the treatment of dyslipidemia in 50 patients with a verified diagnosis of non-alcoholic fatty liver disease and gallbladder cholesterosis was evaluated. The main group (n = 25) of patients received Vazosponin at a dosage of 400 mg per day in addition to dietary recommendations as a hypolipidemic therapy. The control group consisted of 25 patients, which received rosuvastatin at a dose of 10 mg per day in addition to the dietary recommendations. The total duration of observation for each patient was 84 days with three control points: before treatment, on the 28th and the 84th days of therapy. Results. The drug Vazosponin on the 84th day of therapy made it possible to achieve a significant (p < 0.05) and general decrease in total cholesterol by 38 %, LDL – by 17 %, VLDL – by 66 %, TG – by 47 %, CA – by 28 %. To the 84th day of the therapy with Vazosponin positive changes were revealed in the biochemical markers of liver function indicator as a significant (p < 0.05) decrease in levels of ALT – by 42 %, AsAT – by 46 %, GGTP – by 61 %, ALP – by 23 %, total bilirubin – by 41 %. In the main group of patients, adverse effects of therapy have not been established. Conclusion. The inclusion of Vazosponin in the treatment regimens for patients with non-alcoholic fatty liver pathology and gallbladder cholesterosis makes it possible to achieve significant and persistent lipid-lowering and mediated hepatoprotective effects.